Previous study shows the multitarget kinase inhibitors for Aurora kinases and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) imporve antitumor activity over sorafenib in HCC [5]. The gene discussed is KDR; the disease is hepatocellular carcinoma.